XELLIA PHARMS APS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XELLIA PHARMS APS, and what generic alternatives to XELLIA PHARMS APS drugs are available?
XELLIA PHARMS APS has sixteen approved drugs.
There are seven US patents protecting XELLIA PHARMS APS drugs.
There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-eight supplementary protection certificates in nine countries.
Summary for XELLIA PHARMS APS
| International Patents: | 50 |
| US Patents: | 7 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 16 |
Drugs and US Patents for XELLIA PHARMS APS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-002 | Feb 15, 2019 | RX | Yes | Yes | 11,517,609 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-005 | May 13, 2020 | RX | Yes | Yes | 11,628,200 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xellia Pharms Aps | VANCOMYCIN | vancomycin | SOLUTION;INTRAVENOUS, ORAL | 213895-001 | Aug 26, 2021 | DISCN | Yes | No | 10,039,804 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-006 | May 13, 2020 | RX | Yes | Yes | 11,628,200 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XELLIA PHARMS APS Drugs
Supplementary Protection Certificates for XELLIA PHARMS APS Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0536515 | C300244 | Netherlands | ⤷ Sign Up | PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424 |
| 0536515 | 2006/030 | Ireland | ⤷ Sign Up | PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424 |
| 0440372 | SPC/GB02/031 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319 |
| 1280520 | 14/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
